Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of merestinib in non-small cell lung cancer patients with a mutation in the MET protein. The primary outcome will be measured by the overall response to the treatment. This study is being conducted in Boston, Massachusetts. The details Merestinib is an inhibitor of the C-Met...
Read More
In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...
Read More
In a nutshell This trial examined whether osimertinib (Tagrisso) was effective at treating patients with advanced non-small cell lung cancer (NSCLC) that has progressed after EGFR tyrosine-kinase inhibitor (TKI) treatment. The authors concluded that osimertinib is both effective and tolerable as treatment for these patients. Some background...
Read More
In a nutshell The authors aimed to summarize the results of two clinical trials to determine the effectiveness of alectinib as treatment for ALK-mutation positive NSCLC that has progressed beyond crizotinib. They concluded that alectinib is a suitable drug to treat this patient population. This treatment was FDA approved in 2015. Some...
Read More
In a nutshell This study aimed to determine whether EGFR-TKIs, in combination with surgery, is beneficial to patients with operable non-small-cell lung cancer (NSCLC). The authors concluded that patients with EGFR-mutation-positive NSCLC who were treated with both surgery and EGFR-TKIs showed improved survival compared to patients who underwent surgery...
Read More
In a nutshell This study investigated the rate and outcome of trastuzumab (Herceptin) associated cardiac (heart) dysfunction in patients after 1 or 2 years of therapy. The study concluded that for patients treated with adjuvant trastuzamab, the occurrence of cardiac events remained low and that these cardiac events were mostly reversible after...
Read More
In a nutshell This study aimed to determine the efficacy of a combination of the anticancer drugs afatinib (Gilotrif) and paclitaxel (Taxol) to treat non-small cell lung cancer (NSCLC), compared to chemotherapy alone. The study found that a combination of these drugs significantly improved progression free survival (PFS, time from treatment until...
Read More
In a nutshell This study aimed to determine the safety and efficacy of a combination of the anticancer drugs afatinib (Gilotrif) and nimotuzumab (Theraloc) to treat kinase inhibitor resistant EGFR-mutant-NSCLC. The study found that a combination of these drugs had encouraging potential and an acceptable safety profile. Some background A mutation...
Read More
In a nutshell This trial looked at the safety and efficacy of alectinib (Alecensa) in the treatment of patients with ALK-rearranged non-small cell lung cancer (NSCLC) that had progressed after treatment with crizotinib (Xalkori). This trial concluded that alectinib was safe and effective in these patients. Some background Some NSCLCs...
Read MoreIn a nutshell The study investigated whether a common mutation in non small-cell lung cancer (NSCL), an EGFR mutation, can predict metastatic patterns (how cancer spreads to distant parts of the body) in advanced disease. Some background NSCLC is a common type of lung cancer that can have various underlying causes. Mutations...
Read More
In a nutshell This analysis compared the effectiveness and safety of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors and chemotherapy in patients with mutated EGFR non-small cell lung cancer. Some background Many non-small cell lung cancer patients present with a mutated (abnormal) EGFR, which can increase the production...
Read More
